Form 4: Integra Lifesciences Director Receives Stock Units

Integra Lifesciences Holdings Corp. reports a grant of restricted stock units to Director Shaundra Clay, vesting in one year.

Summary

• Director Shaundra Clay was granted 17,700 restricted stock units (RSUs) on May 7, 2026.
• These RSUs are part of the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of IART common stock.
• The RSUs will vest in full on the one-year anniversary of the grant date, May 7, 2027.
• The reporting person has elected to defer the receipt of the vested shares, which will be delivered in a lump sum in the calendar year following the termination of her service on the Board of Directors, unless a later year is elected.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director rather than a significant financial event or strategic shift.

Positives

• Grant of equity awards to a director, indicating a commitment to aligning executive and director interests with shareholders.
• The grant of 17,700 RSUs suggests confidence in the company's future performance to warrant such an award.

Risks

• Potential for share price volatility impacting the value of the RSUs before vesting.
• The deferral election means the actual receipt of shares is tied to future events (termination of service), introducing a timing uncertainty for the director.

Future Outlook

The future outlook is implicitly positive as the company is granting equity awards, suggesting management's belief in future value creation. The vesting schedule and deferral election indicate a long-term alignment strategy.

Industry Context

StockSavvy.ai notes that the issuance of equity awards like RSUs to directors is a common practice in the life sciences industry to attract and retain talent and align their interests with long-term shareholder value. This is standard for companies like Integra Lifesciences operating in a competitive sector.

Stakeholder Impact

• Shareholders: The grant aligns director interests with long-term shareholder value, potentially leading to better governance and strategic decisions.
• Director Shaundra Clay: Receives a financial award tied to company performance and continued service.

Next Steps

• Vesting of RSUs on May 7, 2027.
• Delivery of vested shares in the calendar year following the termination of service on the Board of Directors, as per the deferral election.

Key Dates

Keywords

Form 4, SEC Filing, Integra Lifesciences, IART, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Stock Grant